|AM1710 is a cannabilactone class, selective cannabinoid CB2 receptor agonist . The cannabilactones produce peripheral analgesic activity without the the psychoactive central nervous system side-effects of other CB2 receptor agonists . As expected from its pharmacological profile, AM1710 shows limited blood brain barrier penetration . It has potent agonist activity at rat and mouse CB2 receptors but much reduced activity at human receptors, so is an excellent tool for rodent studies, but it is less useful for translation-to-human studies. In vitro experiments have identified low-potency CB1 inverse agonist activity, but the in vivo relevance of this discovery is undetermined .It is important to note that the sequence heterogeneity in CB2 across species leads to different pharmacologic responses to identical drugs , so extrapolating results from rodent models to humans should be approached with caution.
A 2019 publication of work by Li et al. describes rodent experiments that they undertook to resolve the mechanism(s) by which AM1710 suppresses allodynia caused by distinct pathological processes . Their investigations show that AM1710 is not a broad-spectrum analgesic. In rodent models it is effective in paclitaxel-induced mechanical and cold allodynia but not in mechanically-induced allodynia.